×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NKTR – nektar therapeutics (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NKTR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/3
11:26 am
nktr
Assessing Nektar Therapeutics (NKTR) Valuation After New Multiple Sclerosis Collaboration With UCSF [Yahoo! Finance]
Low
Report
Assessing Nektar Therapeutics (NKTR) Valuation After New Multiple Sclerosis Collaboration With UCSF [Yahoo! Finance]
3/3
04:28 am
nktr
Does Nektar (NKTR)–UCSF MS Collaboration Hint At A Broader Neuroscience Pivot For The Company? [Yahoo! Finance]
Low
Report
Does Nektar (NKTR)–UCSF MS Collaboration Hint At A Broader Neuroscience Pivot For The Company? [Yahoo! Finance]
2/26
06:22 pm
nktr
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets [Yahoo! Finance]
Medium
Report
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets [Yahoo! Finance]
2/26
06:00 pm
nktr
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets
Medium
Report
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets
2/24
06:27 pm
nktr
Nektar Therapeutics to Participate in Two Investor Conferences in March [Yahoo! Finance]
Medium
Report
Nektar Therapeutics to Participate in Two Investor Conferences in March [Yahoo! Finance]
2/24
06:00 pm
nktr
Nektar Therapeutics to Participate in Two Investor Conferences in March
Low
Report
Nektar Therapeutics to Participate in Two Investor Conferences in March
2/23
11:53 am
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at B. Riley Financial, Inc.. They now have a $150.00 price target on the stock, up previously from $105.00.
Low
Report
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at B. Riley Financial, Inc.. They now have a $150.00 price target on the stock, up previously from $105.00.
2/18
08:20 am
nktr
Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy [Seeking Alpha]
Low
Report
Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/20
07:10 pm
nktr
Form 4 NEKTAR THERAPEUTICS For: Feb 18 Filed by: Zalevsky Jonathan
Low
Report
Form 4 NEKTAR THERAPEUTICS For: Feb 18 Filed by: Zalevsky Jonathan
2/20
07:10 pm
nktr
Form 4 NEKTAR THERAPEUTICS For: Feb 18 Filed by: ROBIN HOWARD W
Low
Report
Form 4 NEKTAR THERAPEUTICS For: Feb 18 Filed by: ROBIN HOWARD W
2/18
03:47 pm
nktr
Form 144 NEKTAR THERAPEUTICS Filed by: ROBIN HOWARD W
Low
Report
Form 144 NEKTAR THERAPEUTICS Filed by: ROBIN HOWARD W
2/18
03:15 pm
nktr
Form 144 NEKTAR THERAPEUTICS Filed by: Zalevsky Jonathan
Low
Report
Form 144 NEKTAR THERAPEUTICS Filed by: Zalevsky Jonathan
2/13
05:18 pm
nktr
Form SCHEDULE 13G/A NEKTAR THERAPEUTICS Filed by: SUSQUEHANNA SECURITIES, LLC
Low
Report
Form SCHEDULE 13G/A NEKTAR THERAPEUTICS Filed by: SUSQUEHANNA SECURITIES, LLC
2/13
06:04 am
nktr
Form 8-K NEKTAR THERAPEUTICS For: Feb 11
Low
Report
Form 8-K NEKTAR THERAPEUTICS For: Feb 11
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/10
Form 8-K NEKTAR THERAPEUTICS For: Jan 09
23.0%
9/9 Form 4 NEKTAR THERAPEUTICS For: Sep 05 Filed by: Doberstein Stephen K 11.5%
12/6 Form 8-K NEKTAR THERAPEUTICS For: Dec 05 10.2%
8/9 Nektar Therapeutics (NASDAQ: NKTR) had its price target lowered by analysts at BMO Capital Markets to $41.00. They now have an "outperform" rating on the stock. 10.1%
6/2 Nektar Therapeutics (NASDAQ: NKTR) was given a new $82.00 price target on by analysts at Cowen Inc. They now have a "buy" rating on the stock. 9.9%
2/28 Nektar Therapeutics (NASDAQ: NKTR) had its "outperform" rating re-affirmed by analysts at William Blair. 9.5%
5/9 Nektar Therapeutics (NKTR) Q1 2019 Earnings Call Transcript [The Motley Fool] 9.1%
11/19 Form 8-K NEKTAR THERAPEUTICS For: Nov 13 7.8%
11/7 Nektar Therapeutics (NASDAQ: NKTR) had its price target lowered by analysts at Piper Jaffray Companies from $50.00 to $35.00. They now have an "overweight" rating on the stock. 7.5%
3/13 Nektar Therapeutics (NASDAQ: NKTR) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.1%
9/9 Form 4 NEKTAR THERAPEUTICS For: Sep 05 Filed by: Doberstein Stephen K 11.5%
12/6 Form 8-K NEKTAR THERAPEUTICS For: Dec 05 10.2%
8/9 Nektar Therapeutics (NASDAQ: NKTR) had its price target lowered by analysts at BMO Capital Markets to $41.00. They now have an "outperform" rating on the stock. 10.1%
6/2 Nektar Therapeutics (NASDAQ: NKTR) was given a new $82.00 price target on by analysts at Cowen Inc. They now have a "buy" rating on the stock. 9.9%
2/28 Nektar Therapeutics (NASDAQ: NKTR) had its "outperform" rating re-affirmed by analysts at William Blair. 9.5%
5/9 Nektar Therapeutics (NKTR) Q1 2019 Earnings Call Transcript [The Motley Fool] 9.1%
11/19 Form 8-K NEKTAR THERAPEUTICS For: Nov 13 7.8%
11/7 Nektar Therapeutics (NASDAQ: NKTR) had its price target lowered by analysts at Piper Jaffray Companies from $50.00 to $35.00. They now have an "overweight" rating on the stock. 7.5%
3/13 Nektar Therapeutics (NASDAQ: NKTR) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.1%
TOP News Decliners
8/8
Q2/2019 6/30/2019 EPS -0.630 ZacksConsensus -0.800 ActVsEst 0.170 - Beat
-29.3%
1/14 Nektar Therapeutics (NKTR) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow [Seeking Alpha] -16.0%
3/13 Form 4 NEKTAR THERAPEUTICS For: Mar 11 Filed by: CHESS ROBERT -13.4%
8/10 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm -11.2%
11/15 Form 4 NEKTAR THERAPEUTICS For: Nov 13 Filed by: Labrucherie Gil M -8.4%
5/15 Nektar Therapeutics Announces Five Accepted Abstracts at 2019 American Society of Clinical Oncology's (ASCO) Annual Meeting -7.8%
10/8 Nektar Therapeutics (NASDAQ: NKTR) was downgraded by analysts at Goldman Sachs Group Inc from a "buy" rating to a "sell" rating. They now have a $16.00 price target on the stock, down previously from $54.00. -7.5%
8/4 More Potential FDA Opioid Delays In Nektar's Wake [Seeking Alpha] -7.4%
9/26 Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Triple-Negative Breast Cancer Patients at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference -6.8%
10/1 Form 4 NEKTAR THERAPEUTICS For: Sep 27 Filed by: CHESS ROBERT -6.0%
1/14 Nektar Therapeutics (NKTR) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow [Seeking Alpha] -16.0%
3/13 Form 4 NEKTAR THERAPEUTICS For: Mar 11 Filed by: CHESS ROBERT -13.4%
8/10 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm -11.2%
11/15 Form 4 NEKTAR THERAPEUTICS For: Nov 13 Filed by: Labrucherie Gil M -8.4%
5/15 Nektar Therapeutics Announces Five Accepted Abstracts at 2019 American Society of Clinical Oncology's (ASCO) Annual Meeting -7.8%
10/8 Nektar Therapeutics (NASDAQ: NKTR) was downgraded by analysts at Goldman Sachs Group Inc from a "buy" rating to a "sell" rating. They now have a $16.00 price target on the stock, down previously from $54.00. -7.5%
8/4 More Potential FDA Opioid Delays In Nektar's Wake [Seeking Alpha] -7.4%
9/26 Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Triple-Negative Breast Cancer Patients at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference -6.8%
10/1 Form 4 NEKTAR THERAPEUTICS For: Sep 27 Filed by: CHESS ROBERT -6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: